Onkos Surgical announced the completion of the company’s first ELEOS Limb Salvage System procedure using uDesign Patient Solutions. uDesign delivers an interactive experience, enabling a personalized planning approach for each patient. The first surgery was conducted by Steven Gitelis, M.D., of Rush University Medical Center in Chicago.
Onkos Surgical, Inc., a specialty medtech company focused on surgical oncology, today announced that it closed a $17.6 million round in Series B funding. Canaan Partners led the funding round and existing investors 1315 Capital and 3D Systems also participated. Onkos will use the new funding to expand its sales, marketing, and R&D platforms to …
Onkos Surgical, an innovative surgical oncology company, has announced today it has partnered with PatientIQ, a healthcare data, research and analytics technology company, to launch a platform for the collection of clinical data for surgical oncology patients.
An experienced management team, led by Joseph M. Limber, in partnership with Ampersand Capital Partners and 1315 Capital, has completed the acquisition of Genoptix, Inc. from Novartis. The financial terms of the transaction are not being disclosed. Headquartered in Carlsbad, California, Genoptix is a recognized leader in its field, and is one of the largest …
A new study published in Journal of the International Society of Sports Nutrition shows the combination of amylopectin and chromium in Nutrition 21’s patented ingredient Velositol doubles the muscle protein synthesis rate compared to what was seen when using whey protein alone.
An experienced management group led by Joseph M. Limber, in partnership with Ampersand Capital Partners and 1315 Capital, has entered into a definitive agreement to acquire the commercial laboratory of Genoptix, Inc., a Novartis company that specializes in oncology diagnostics and informatics services. This transaction is expected to close in the first quarter of 2017 …
Encore Dermatology Inc., a privately held dermatology company that specializes in developing and commercializing novel prescription products for improving skin health, announced today the availability of TridesilonTM (desonide) Cream, 0.05% in a 60g tube. TridesilonTM Cream, 0.05% is a low-potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Past and present commissioners of the U.S. Food and Drug Administration, both with ties to Duke University, are among the speakers headlining the Council for Entrepreneurial Development’s 26th annual Life Science Conference next month in Raleigh. Confirmed speakers at the conference include Adele Oliva, Ibraheem Badejo, and James C. Greenwood.
1315 Capital, LLC, an expansion and growth equity firm that invests in commercial-stage specialty pharmaceutical, medical technology, and healthcare services companies today announced the recent expansion of its team with the addition of Edward Chan.
Onkos Surgical has announced today it has received clearance from the U.S. Food and Drug Administration to market the ELEOS™ Limb Salvage System to treat patients with significant bone loss due to cancer, trauma, or previous surgical procedures.